Gritstone bio, Inc.
https://gritstonebio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gritstone bio, Inc.
The BioPharma Shares Rising On Omicron Hopes And Fears
Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.
AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
Coronavirus Update: FDA Approves Pfizer/BioNTech's Comirnaty
The FDA granted an expected, though long-awaited, approval to the COVID-19 vaccine. Also, Korean regulators have begun a review of Russian vaccine CoviVac, while Bavarian Nordic has initiated a Phase II study of its vaccine booster candidate and received a commitment for up to DKK 800m from the Danish government.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Gritstone Oncology, Inc.